A groundbreaking clinical trial led by scientists at Lawson Health Research Institute and London Health Sciences Centre is exploring the use of fecal microbiota transplantation (FMT) via oral capsules—commonly referred to as “poop pills”—to enhance chemotherapy efficacy in patients with advanced pancreatic cancer. This innovative approach aims to modulate the gut microbiome, potentially improving patients’ responses to treatment.
Pancreatic cancer is notably challenging to treat, with a five-year survival rate of approximately 13%. The tumor microenvironment, comprising various microorganisms, can influence chemotherapy resistance. By introducing beneficial microbes through FMT, researchers hope to alter this environment favorably, thereby enhancing treatment outcomes. Click for More Details
